CYP3A4 and rhabdomyolysis: This metabolic profile makes atorvastatin vulnerable to interactions with CYP3A4 inhibitors, such as itraconazole, ritonavir, and GFJ, potentially raising systemic drug levels and the risk of adverse effects like myopathy or rhabdomyolysis [109].